Prolactinoma is the most common hypersecreting tumor of pituitary gland [1] and medical therapy with dopamine agonists (DAs) is recommended as first line intervention. DA therapy is effective in reversing hyperprolactinemia and its consequences-secondary hypogonadism and galactorrhea and may induce tumor shrinkage [2] . DA, such as cabergoline and bromocriptine, lead to prolactin normalization by acting through D2 receptors on the lactotroph cells. In many cases DA therapy is necessary for extended period of time, even life-long. While more common side effects of DAs such as headaches, dizziness and gastrointestinal disturbance are well known, a less recognized side effect of DA therapy is development of impulse control disorders (ICDs).
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ICDs include hypersexuality, gambling, punding, compulsive shopping and binge eating and are thought to be mediated through dopamine receptors in the reward pathways of the mesolimbic system [3] . In a case-control study of 77 patients with DA treated prolactinomas and 70 patients with non-functioning pituitary tumors, prevalence of ICDs was reported to be 25 and 17%, respectively [4] . However, striking differences were observed only for men in the DA treated-prolactinoma group who were almost 10 times more likely to develop an ICD when compared to men with non-functioning pituitary adenomas [4] . Moreover, authors noted a between-group significant difference only for hypersexuality which affected 10 patients (7 men) [4] .
In the current report, De Souza et al. describe findings in 8 men with DA treated prolactinomas identified from their clinics who developed hypersexuality. Authors suggest that a synergy between DA therapy and restoration of eugonadal state may contribute to development of hypersexuality and propose the term "dopa-testotoxicosis" to describe these occurrences [5] . In their case series, men developed hypersexuality within days to years after commencing DA therapy and this coincided with normalization of prolactin and improvement of testosterone concentrations. Interestingly, though hypersexuality was a predominant ICD, both Bancos et al. and De Souza et al. reported that a third of patients in their cohort (7/19 and 2/8, respectively) developed multiple ICDs [4, 5] . The term "dopa-testotoxicosis" does not account for ICD development other than hypersexuality, or the development of hypersexuality in women. In addition, it is difficult to draw conclusions that a relative increase in testosterone concentrations (as none of the patients had supraphysiological testosterone concentrations) played a major contribution to developing hypersexuality, especially, given the design of both studies. Prospective studies are needed to reveal any temporal relationship to testosterone concentrations and to define any other predisposing factors to developing hypersexuality and other ICDs.
Based on the published case reports of hypersexuality reported in patients with DA treated prolactinomas, severity of presentation varies, but can be devastating to patients and their families. While some patients experience no or mild interference of symptoms with relationship and work, in others, symptoms can lead to loss of income, divorce, friends and family estrangement, promiscuity and legal troubles. Many times, since behavioral changes are not typical drug side effects, patients are not aware of possible causal relationship to DA therapy and may not volunteer the It is reassuring to note that hypersexuality resolved either after DA reduction or cessation [4, 5] .
Whether there is a DA dose or temporal relationship present, is unknown. It is unclear if there are predisposing factors to the development of ICD with DA therapy. Prospective observational trials are needed to determine a true prevalence and gender distribution of ICDs, risk factors for its development, and potential relationship to dose and duration of DA therapy.
What are the clinical implications with currently limited evidence? Endocrinologists need to recognize the possibility of ICD in relation to DA therapy, particularly its potential harmful effects and counsel patients appropriately.
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